SCHEMBL1746506

SCHEMBL1746506

CN(Cc1ccc(C=O)cc1)c1nc(-c2ccccc2)cs1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.57
MEN1 O00255 5/20 0.57
L3MBTL1 Q9Y468 2/20 0.57
GSTO1 P78417 7/20 0.54
CPB1 P15086 1/20 0.50
NPSR1 Q6W5P4 1/20 0.48
RAB9A P51151 3/20 0.46
NPC1 O15118 2/20 0.46
MAPT P10636 2/20 0.45
TSHR P16473 2/20 0.45
ALDH1A1 P00352 2/20 0.45
TP53 P04637 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
KDM4E B2RXH2 1/20 0.45
USP2 O75604 1/20 0.45
LMNA P02545 1/20 0.45
HPGD P15428 1/20 0.45
NFKB1 P19838 1/20 0.45
MAPK1 P28482 1/20 0.45
MMP13 P45452 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18674599 0.87 KMT2A (0.64) KMT2AMEN1L3MBTL1GSTO1CPB1
SCHEMBL4261635 0.85 KMT2A (0.55) KMT2AMEN1L3MBTL1GSTO1CPB1
SCHEMBL4261629 0.85 KMT2A (0.55) KMT2AMEN1L3MBTL1GSTO1CPB1
SCHEMBL1746662 0.83 KMT2A (0.57) KMT2AMEN1L3MBTL1GSTO1CPB1
SCHEMBL1746621 0.82 KMT2A (0.60) KMT2AMEN1L3MBTL1GSTO1CPB1
SCHEMBL1747119 0.82 KMT2A (0.52) KMT2AMEN1L3MBTL1GSTO1CPB1
SCHEMBL3622785 0.81 KMT2A (0.53) KMT2AMEN1L3MBTL1GSTO1CPB1
SCHEMBL1747124 0.81 KMT2A (0.58) KMT2AMEN1L3MBTL1GSTO1CPB1
SCHEMBL6806950 0.80 ATP4A (0.50) KMT2AMEN1GSTO1NPSR1RAB9A
SCHEMBL1747118 0.80 KMT2A (0.52) KMT2AMEN1L3MBTL1GSTO1CPB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
CN-1735408-A Receptor function controlling agent TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2006-02-15 CN disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR KMT2A 4408/4885MEN1 2579/4885L3MBTL1 4392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.